- H.C. Wainwright has initiated GeoVax Labs ( NASDAQ: GOVX ) with a buy highlighting its pipeline of cancer immunotherapy and infectious diseases candidates.
- The firm has an $8 price target (~820% upside based on Tuesday's close).
- Shares are up 16% in Thursday morning trading.
- Analyst Vernon Bernardino said that GEOCM04S1, currently in phase 2, "has potential to confer robust, durable protection against SARS-CoV-2 infection."
- Gedeptin, a cancer immunotherapy in phase 1/2 for advanced head and neck cancer solid tumors, has demonstrated the ability to shrink tumors and could potentially be used in combination with immune checkpoint inhibitors, he added.
- Finally, GeoVax's ( GOVX ) MVA-VLP technology "demonstrates versatile application in the creation of single-design vaccines active against multiple infectious diseases and solid cancers," according to Bernardino.
- Seeking Alpha's Quant Rating views GeoVax as a buy with high marks for momentum and growth .
For further details see:
GeoVax Labs initiated at buy at Wainwright on vaccines for cancer, infectious diseases